Skip to main content

Table 2 Prevalence of persistent pain according to detection method, tumor and women’s characteristics

From: Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs

  Persistent paina  
  N (%) P-value
Women’s characteristics
 Age (n = 1045)   0.483
  50–54 (n = 305) 36 (11.8)  
  55–59 (n = 281) 37 (13.2)  
  60–64 (n = 275) 29 (10.5)  
  65–70 (n = 184) 16 (8.7)  
 Charlson index (n = 1045)   <0.001
  0 (n = 769) 65 (8.5)  
  1 (n = 180) 32 (17.8)  
   > =2 (n = 96) 21 (21.9)  
Detection method (n = 1045)
  Screen-detected tumors (n = 723) 93 (12.9) <0.05
  Interval tumors (n = 322) 25 (7.8)  
Tumor characteristics
 Tumor size (n = 932)   0.907
   < =10 mm (n = 237) 14 (5.9)  
  11 to 20 mm (n = 387) 28 (7.2)  
  21 to 50 mm (n = 265) 19 (7.2)  
   > 50 mm (n = 43) 2 (4.7)  
 Lymph node involvement (n = 1042)   0.564
  Negative (n = 713) 78 (10.9)  
  Positive (n = 329) 40 (12.2)  
 Number of positive nodes (n = 866)   0.442
   = <3 (n = 781) 54 (6.9)  
  4–20 (n = 77) 7 (9.1)  
   > 20 (n = 8) 1 (12.5)  
 Histological type (n = 1038)   <0.05
  Ductal (n = 763) 94 (12.3)  
  In situ (n = 93) 2 (2.2)  
  Lobular (n = 98) 14 (14.3)  
  Othter (n = 84) 7 (8.3)  
 Focality (n = 891)   0.461
  Unifocal (n = 741) 56 (7.6)  
  Multifocal and/or multicentric (n = 150) 14 (9.3)  
 Histological grade (n = 905)   0.101
  I (n = 228) 19 (8.3)  
  II (n = 348) 46 (13.2)  
  III (n = 270) 25 (9.3)  
  Not applicable (n = 59) 3 (5.1)  
 Tumor phenotype (n = 763)   0.291
  Luminal A (n = 404) 41 (10.1)  
  Luminal B (n = 207) 12 (5.8)  
  HER2 (n = 67) 5 (7.5)  
  Triple negative (n = 85) 9 (10.6)  
  1. aPercentages were computed as follows: number of women with persistent pain divided by the total number of women for each category